Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
- Trade
- Markets
- Copy
- Contests
- News
- 24/7
- Calendar
- Q&A
- Chats
Trending
SYMBOL
LAST
BID
ASK
HIGH
LOW
NET CHG.
%CHG.
SPREAD
SPX
S&P 500 Index
6840.50
6840.50
6840.50
6864.93
6837.42
-6.01
-0.09%
--
DJI
Dow Jones Industrial Average
47560.28
47560.28
47560.28
47957.79
47533.60
-179.03
-0.38%
--
IXIC
NASDAQ Composite Index
23576.48
23576.48
23576.48
23616.46
23449.73
+30.58
+ 0.13%
--
USDX
US Dollar Index
99.080
99.160
99.080
99.210
98.960
-0.100
-0.10%
--
EURUSD
Euro / US Dollar
1.16350
1.16358
1.16350
1.16575
1.16215
+0.00093
+ 0.08%
--
GBPUSD
Pound Sterling / US Dollar
1.33155
1.33163
1.33155
1.33268
1.32894
+0.00204
+ 0.15%
--
XAUUSD
Gold / US Dollar
4197.89
4198.32
4197.89
4218.67
4187.63
-9.28
-0.22%
--
WTI
Light Sweet Crude Oil
58.196
58.226
58.196
58.507
57.945
+0.041
+ 0.07%
--
- All
- Chatrooms
- Groups
- Friends
Connecting
.
.
.
- All
- Russia-Ukraine Conflict
- Middle East Flashpoint
NRx Pharmaceuticals (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment
FinanceWire
Austin, Texas, United States, December 3rd, 2025, FinanceWire
NRx Pharmaceuticals , a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug filing for NRX-101 to include use of the drug in combination with Transcranial Magnetic Stimulation for depression, including suicidal depression. The update follows evidence suggesting NRX-101 may significantly enhance TMS outcomes, with published studies showing more than two-fold improvements in symptom reduction and clinical response rates exceeding 80%. The Company noted NRX-101’s D-cycloserine component appears to augment neuroplasticity associated with TMS, while its low-dose lurasidone is intended to mitigate D-cycloserine’s known risk of low-grade hallucinations. NRx said it aims to validate the findings in a well-controlled trial of about 120 participants and is in partnership discussions with TMS device manufacturers to pursue joint registration studies and potential label augmentation.
To view the full press release, visit https://ibn.fm/LT0dZ
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
Contact
IBN
www.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com
Risk Warnings and Disclaimers
You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
Copyright © 2025 FastBull Ltd
728 RM B 7/F GEE LOK IND BLDG NO 34 HUNG TO RD KWUN TONG KLN HONG KONG
Risk Disclosure
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Become a signal provider
Help Center
Dark Mode
Price Up/Down Colors
Log In
Sign Up